Compugen Ltd. (CGEN) to Receive $5 Million for R&D Initiatives
Before the opening bell today, Compugen Ltd. announced that it has entered into a financing agreement with Baize Investments (Israel) Ltd., a private corporation investing, inter alia, in innovative medical technologies, for $5,000,000 in R&D funding. In exchange, Baize Investments has obtained a financial interest in five designated Compugen-discovered molecules and has been issued a warrant to purchase 500,000 Compugen shares at an exercise price of $6.00 per share, expiring mid-2013. Baize Investments' financial interest in the five molecules consists of the right to receive up to 10% of certain future payments received by Compugen from third parties in the…